Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with IMRT for resected head and neck cancer
NCT00956007Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Mar 2010
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by NRG Oncology. Started Mar 2010; status: active, not recruiting.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00956007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956007.